CN108210975B - Collagen Dressing for Acne Treatment - Google Patents
Collagen Dressing for Acne Treatment Download PDFInfo
- Publication number
- CN108210975B CN108210975B CN201810119795.6A CN201810119795A CN108210975B CN 108210975 B CN108210975 B CN 108210975B CN 201810119795 A CN201810119795 A CN 201810119795A CN 108210975 B CN108210975 B CN 108210975B
- Authority
- CN
- China
- Prior art keywords
- dressing
- marine
- hydrolyzed collagen
- daltons
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 58
- 108010035532 Collagen Proteins 0.000 title claims abstract description 58
- 229920001436 collagen Polymers 0.000 title claims abstract description 58
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 30
- 206010000496 acne Diseases 0.000 title claims abstract description 30
- 235000002961 Aloe barbadensis Nutrition 0.000 claims abstract description 26
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 25
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims abstract description 18
- 239000004745 nonwoven fabric Substances 0.000 claims abstract description 17
- 239000000843 powder Substances 0.000 claims abstract description 17
- 239000007788 liquid Substances 0.000 claims abstract description 16
- 229920001661 Chitosan Polymers 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims abstract description 8
- 229920000642 polymer Polymers 0.000 claims description 4
- 244000144927 Aloe barbadensis Species 0.000 claims 4
- 244000186892 Aloe vera Species 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 5
- 230000019612 pigmentation Effects 0.000 abstract description 5
- 230000008439 repair process Effects 0.000 abstract description 4
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 3
- 239000000758 substrate Substances 0.000 abstract description 3
- 231100000344 non-irritating Toxicity 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 22
- 230000005764 inhibitory process Effects 0.000 description 17
- 102000003425 Tyrosinase Human genes 0.000 description 15
- 108060008724 Tyrosinase Proteins 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 8
- 230000003750 conditioning effect Effects 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 238000011895 specific detection Methods 0.000 description 5
- 241000186427 Cutibacterium acnes Species 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 229940055019 propionibacterium acne Drugs 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 3
- 229960004705 kojic acid Drugs 0.000 description 3
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 208000032544 Cicatrix Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002910 effect on acne Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 230000037384 skin absorption Effects 0.000 description 2
- 231100000274 skin absorption Toxicity 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical group [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940074774 glycyrrhizinate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/07—Stiffening bandages
- A61L15/10—Stiffening bandages containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A61L15/325—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/64—Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及用于治疗痤疮的胶原敷料。本发明所述胶原敷料包括辅料液和敷料基底,其中,所述敷料液主要由1~10份海洋水解胶原蛋白、0.5~4份甘草酸二钾、0.2~1份芦荟凝胶粉和1000份水制备而成,所述基底为无纺布,优选为壳聚糖无纺布。本发明所述胶原敷料以纯天然材料为主、简单安全、组织相容性好、无刺激,具有良好的抑菌和减少痤疮引起的色素沉积作用,对痤疮具有良好的治疗和修复作用。
The present invention relates to collagen dressings for the treatment of acne. The collagen dressing of the present invention includes an auxiliary liquid and a dressing base, wherein the dressing liquid is mainly composed of 1-10 parts of marine hydrolyzed collagen, 0.5-4 parts of dipotassium glycyrrhizinate, 0.2-1 part of aloe vera gel powder and 1000 parts of It is prepared from water, and the substrate is a non-woven fabric, preferably a chitosan non-woven fabric. The collagen dressing of the present invention is mainly made of pure natural materials, is simple and safe, has good tissue compatibility, and is non-irritating, has good antibacterial and pigmentation reduction effects caused by acne, and has good acne treatment and repair effects.
Description
技术领域technical field
本发明涉及敷料领域,具体而言,涉及用于治疗痤疮的胶原敷料。The present invention relates to the field of dressings, in particular to collagen dressings for treating acne.
背景技术Background technique
痤疮(Acne vulgaris),又称粉刺(Acne),是一种常见的皮肤病,年龄在11~30岁之间的人群中有80%的人患此病,多发于面部、背部、胸等富含皮脂腺的部位。痤疮可以持续多年,导致容貌损毁或留下永久的瘢痕并对患者的心理成长造成严重的负面影响。Acne (Acne vulgaris), also known as acne (Acne), is a common skin disease, 80% of people between the ages of 11 and 30 suffer from this disease, mostly on the face, back, chest, etc. Areas containing sebaceous glands. Acne can persist for years, causing disfigurement or permanent scarring and having a severe negative impact on the patient's psychological growth.
病原学分析认为痤疮的严重程度与表皮的金黄色葡萄球菌和皮下的痤疮丙酸杆菌有关,如何有效地抑制和杀灭这两种细菌是治疗痤疮的关键。Etiological analysis suggests that the severity of acne is related to epidermal Staphylococcus aureus and subcutaneous Propionibacterium acnes, and how to effectively inhibit and kill these two bacteria is the key to acne treatment.
现代治疗痤疮主要以口服抗菌药物、激素、维A酸类药物及外用消炎药为主,疗程比较长、病情易复发、且易产生不良反应等问题,而且易形成瘢痕或色素沉着。因此,研制一种更为安全、温和、持久且功效全面的产品已成为众望所归。Modern acne treatment is mainly based on oral antibiotics, hormones, retinoic acid drugs and topical anti-inflammatory drugs. The course of treatment is relatively long, the disease is easy to recur, and it is easy to produce adverse reactions, and it is easy to form scars or pigmentation. Therefore, the development of a safer, gentler, longer-lasting and more comprehensive product has become a popular choice.
有鉴于此,特提出本发明。In view of this, the present invention is proposed.
发明内容SUMMARY OF THE INVENTION
本发明的第一目的在于提供一种用于治疗痤疮的敷料液,所述敷料液以纯天然材料为主、简单安全、组织相容性好、无刺激,具有良好的抑菌和减少痤疮引起的色素沉积作用,对痤疮具有良好的治疗和修复作用。The first object of the present invention is to provide a dressing liquid for treating acne, which is mainly made of pure natural materials, is simple and safe, has good tissue compatibility, is non-irritating, has good bacteriostasis and reduces acne caused by acne. Pigmentation effect, has a good treatment and repair effect on acne.
本发明的第二目的在于提供一种用于治疗痤疮的敷料,所述敷料包括前述敷料基底和前述敷料液,使用方便,对痤疮具有良好的治疗和修复作用。The second object of the present invention is to provide a dressing for treating acne, the dressing comprising the aforementioned dressing base and the aforementioned dressing liquid, which is convenient to use and has good therapeutic and repairing effects on acne.
为实现本发明的上述目的,特采用以下技术方案:In order to realize the above-mentioned purpose of the present invention, the following technical solutions are specially adopted:
用于治疗痤疮的敷料液,按重量份计,所述敷料液主要由1~10份海洋水解胶原蛋白、0.5~4份甘草酸二钾、0.2~1份芦荟凝胶粉和1000份水制备而成。A dressing liquid for treating acne, in parts by weight, the dressing liquid is mainly prepared from 1-10 parts of marine hydrolyzed collagen, 0.5-4 parts of dipotassium glycyrrhizinate, 0.2-1 part of aloe vera gel powder and 1000 parts of water made.
本发明所述敷料液的制备原料包括海洋水解胶原蛋白、甘草酸二钾、芦荟凝胶粉。其中,甘草酸二钾作为皮肤调理剂,具有抑菌、消炎镇静、退红肿促进愈合的作用,经过甘草酸二钾的调理,能够从整体上缓解痤疮患者面部皮肤的微生物感染和炎症,改善面部皮肤的整体生理状况,使皮肤处于吸收、修复能力强的生理状态,有利于后续海洋水解胶原蛋白以及芦荟凝胶的渗透和起效,另外甘草酸二钾能够深入皮下,对痤疮丙酸杆菌也具有良好的抑制作用。而芦荟凝胶中含有大量的酚类、多糖和氨基酸,对体外金黄色葡萄球菌、大肠杆菌和皮下的痤疮丙酸杆菌等具有良好的抑制作用,且芦荟多糖和维生素对皮肤有良好的滋润与增白作用。因此,芦荟凝胶对引发痤疮的细菌具有针对性的抑制作用,能够起到标本兼治的功效,同时,其美白和滋润功效对皮肤的修复也有极大益处。而海洋水解胶原蛋白能够渗透到角质层、真皮层,其酪氨酸残基可以与皮肤中的酪氨酸竞争,抑制酪氨酸酶催化酪氨酸转化为多巴醌,从一定程度上防止黑色素的形成,减少色素沉积。再者,海洋水解胶原蛋白、甘草酸二钾、芦荟凝胶粉均为纯天然提取物,组织相容性好,对皮肤无刺激,安全可靠。The preparation raw materials of the dressing liquid of the present invention include marine hydrolyzed collagen, dipotassium glycyrrhizate and aloe vera gel powder. Among them, as a skin conditioning agent, dipotassium glycyrrhizate has the functions of antibacterial, anti-inflammatory and calming, reducing redness and promoting healing. After conditioning with dipotassium glycyrrhizate, it can relieve the microbial infection and inflammation of the facial skin of acne patients as a whole, and improve the facial skin. The overall physiological condition of the skin makes the skin in a physiological state with strong absorption and repair ability, which is conducive to the subsequent penetration and effect of marine hydrolyzed collagen and aloe vera gel. Has a good inhibitory effect. Aloe vera gel contains a large amount of phenols, polysaccharides and amino acids, which has a good inhibitory effect on Staphylococcus aureus, Escherichia coli and subcutaneous Propionibacterium acnes in vitro, and aloe vera polysaccharides and vitamins have good moisturizing and moisturizing effect on the skin. whitening effect. Therefore, aloe vera gel has a targeted inhibitory effect on the bacteria that cause acne, which can cure both the symptoms and symptoms. At the same time, its whitening and moisturizing effects are also of great benefit to the repair of the skin. The marine hydrolyzed collagen can penetrate into the stratum corneum and dermis, and its tyrosine residues can compete with tyrosine in the skin, inhibiting the conversion of tyrosine into dopaquinone by tyrosinase catalyzed by tyrosinase, preventing to a certain extent The formation of melanin, reducing pigmentation. Furthermore, marine hydrolyzed collagen, dipotassium glycyrrhizate, and aloe vera gel powder are all natural extracts with good histocompatibility, no irritation to the skin, and are safe and reliable.
综上所述,本发明所述敷料液中的甘草酸二钾、芦荟凝胶和海洋水解胶原蛋白在整体上具有相互配合、协同增效的作用,其中,甘草酸二钾的调理作用可从整体上改善患者皮肤状态,增强皮肤对芦荟凝胶和海洋水解蛋白的吸收利用,而芦荟凝胶对病菌的抑制作用能够进一步增强甘草酸二钾对皮肤的调理作用,同时其良好的保水性,有利于皮肤对甘草酸钾和海洋水解胶原蛋白的吸收。而海洋水解胶原蛋白不但能够抑制色素的沉积,同时还能为皮肤的新陈代谢提供所述氨基酸,改善皮肤细胞的生存环境,增强皮肤的活力和抵抗力,协助甘草酸二钾与芦荟凝胶发挥调理、治疗作用。To sum up, the dipotassium glycyrrhizate, aloe vera gel and marine hydrolyzed collagen in the dressing liquid of the present invention have the functions of mutual coordination and synergy on the whole, wherein the conditioning effect of dipotassium glycyrrhizate can be from Overall, it improves the skin condition of patients and enhances the skin's absorption and utilization of aloe vera gel and marine hydrolyzed protein. The inhibitory effect of aloe vera gel on bacteria can further enhance the conditioning effect of dipotassium glycyrrhizinate on the skin. At the same time, its good water retention, Facilitates skin absorption of potassium glycyrrhizinate and marine hydrolyzed collagen. The marine hydrolyzed collagen can not only inhibit the deposition of pigment, but also provide the amino acids for skin metabolism, improve the living environment of skin cells, enhance the vitality and resistance of the skin, and assist dipotassium glycyrrhizate and aloe vera gel in conditioning ,Therapeutic effect.
在一些具体的实施方式中,按重量份计,所述海洋水解胶原蛋白为1 份、5份或10份。In some specific embodiments, the marine hydrolyzed collagen is 1 part, 5 parts or 10 parts by weight.
在一些具体的实施方式中,所述甘草酸二钾为0.5份、2份或4份。In some specific embodiments, the dipotassium glycyrrhizinate is 0.5 parts, 2 parts, or 4 parts.
在一些具体的实施方式中,所述芦荟凝胶粉为0.2份、0.5份或1份。In some specific embodiments, the aloe vera gel powder is 0.2 part, 0.5 part or 1 part.
在一些具体的实施方式中,所述海洋水解胶原蛋白的分子量为 400~1500道尔顿,例如,400道尔顿、500道尔顿、600道尔顿、700道尔顿、800道尔顿、900道尔顿、1000道尔顿、1100道尔顿、1200道尔顿、 1300道尔顿或1400道尔顿。In some specific embodiments, the molecular weight of the marine hydrolyzed collagen is 400-1500 Daltons, for example, 400 Daltons, 500 Daltons, 600 Daltons, 700 Daltons, 800 Daltons , 900 Daltons, 1000 Daltons, 1100 Daltons, 1200 Daltons, 1300 Daltons or 1400 Daltons.
在一些具体的实施方式中,所述海洋水解胶原蛋白的聚合物分散性指数(polymerdispersity index,PDI)≤3.0,优选地,PDI≤2.4,更优选地, PDI≤2.0。In some specific embodiments, the polymer dispersity index (PDI) of the marine hydrolyzed collagen is ≤3.0, preferably, PDI≤2.4, more preferably, PDI≤2.0.
在一些具体的实施方式中,所述海洋水解胶原蛋白选自Nippi水解胶原蛋白、罗赛洛水解胶原蛋白、东方海洋水解胶原蛋白或山东天久水解胶原蛋白。In some specific embodiments, the marine hydrolyzed collagen is selected from Nippi hydrolyzed collagen, Rousselot hydrolyzed collagen, Oriental marine hydrolyzed collagen or Shandong Tianjiu hydrolyzed collagen.
本发明还意外地发现,分子量大小和PDI值影响海洋水解胶原蛋白对酪氨酸酶的抑制作用。因此,本发明所述方法还对海洋水解蛋白的分子量与PDI值进行限定,在本发明前述范围内的海洋水解蛋白具有良好的酪氨酸酶抑制效果。The present invention also unexpectedly found that the molecular weight and PDI value affect the inhibitory effect of marine hydrolyzed collagen on tyrosinase. Therefore, the method of the present invention also limits the molecular weight and PDI value of the marine hydrolyzed protein, and the marine hydrolyzed protein within the aforementioned scope of the present invention has a good tyrosinase inhibitory effect.
在一些具体的实施方式中,为适合人体皮肤使用,本发明所述敷料液的pH值为4.0~6.0,优选为5.0~6.0。In some specific embodiments, in order to be suitable for use on human skin, the pH value of the dressing solution of the present invention is 4.0-6.0, preferably 5.0-6.0.
在一些具体的实施方式中,所述芦荟凝胶粉为库拉索芦荟凝胶粉。In some specific embodiments, the aloe vera gel powder is aloe vera gel powder.
本发明还涉及用于治疗痤疮的敷料,所述敷料包括敷料基底和前述敷料液。The present invention also relates to a dressing for the treatment of acne comprising a dressing base and the aforementioned dressing solution.
在一些具体的实施方式中,所述敷料基底为无纺布,优选地,所述无纺布为壳聚糖无纺布;更优选地,所述无纺布中壳聚糖的质量分数≥20%,或≥30%,或≥50%,或=100%。In some specific embodiments, the dressing substrate is a non-woven fabric, preferably, the non-woven fabric is a chitosan non-woven fabric; more preferably, the mass fraction of chitosan in the non-woven fabric is ≥ 20%, or ≥ 30%, or ≥ 50%, or = 100%.
本发明前述敷料的基底为含壳聚糖的无纺布,其中的壳聚糖具有优良的抗菌活性,对金黄色葡萄球菌、大肠杆菌、乳酸杆菌等常见菌种具有很好的抑菌作用,能够进一步增强所述敷料对痤疮的治疗效果。The substrate of the aforementioned dressing of the present invention is a non-woven fabric containing chitosan, wherein the chitosan has excellent antibacterial activity, and has a good bacteriostatic effect on common strains such as Staphylococcus aureus, Escherichia coli, Lactobacillus, etc. The therapeutic effect of the dressing on acne can be further enhanced.
在一些具体的实施方式中,所述敷料基底浸润在所述敷料液中,或者,所述敷料基底和所述敷料液独立包装。In some specific embodiments, the dressing base is soaked in the dressing solution, or the dressing base and the dressing solution are packaged separately.
与现有技术相比,本发明的有益效果为:Compared with the prior art, the beneficial effects of the present invention are:
(1)本发明所述敷料液、敷料通过甘草酸二钾、芦荟凝胶活性物质、海洋水解胶原多肽和/或壳聚糖的配伍,具有杀灭痤疮主要致病菌、调理皮肤和抑制色素沉积的作用,在整体上对痤疮具有良好的的治疗和修复作用。(1) Dressing liquid of the present invention, dressing are through the compatibility of dipotassium glycyrrhizate, aloe vera gel active substance, marine hydrolyzed collagen polypeptide and/or chitosan, and have the functions of killing the main pathogenic bacteria of acne, conditioning the skin and inhibiting pigmentation. The effect of deposition has a good therapeutic and repairing effect on acne as a whole.
(2)本发明所述敷料液和敷料以纯天然材料为主,具有简单安全、组织相容性好、对皮肤无刺激的优点。(2) The dressing liquid and dressing of the present invention are mainly made of pure natural materials, and have the advantages of simplicity and safety, good tissue compatibility, and no irritation to the skin.
(3)本发明还进一步限定海洋水解胶原蛋白的分子量和PDI值,可进一步增强所述敷料液和敷料对酪氨酸酶活性的抑制作用。(3) The present invention further defines the molecular weight and PDI value of marine hydrolyzed collagen, which can further enhance the inhibitory effect of the dressing solution and dressing on tyrosinase activity.
附图说明Description of drawings
为了更清楚地说明本发明具体实施方式或现有技术中的技术方案,下面将对具体实施方式或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图是本发明的一些实施方式,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。In order to illustrate the specific embodiments of the present invention or the technical solutions in the prior art more clearly, the following briefly introduces the accompanying drawings that need to be used in the description of the specific embodiments or the prior art. Obviously, the accompanying drawings in the following description The drawings are some embodiments of the present invention. For those of ordinary skill in the art, other drawings can also be obtained based on these drawings without creative efforts.
图1为治疗结束后受试者右脸的皮肤状况;Fig. 1 is the skin condition of the subject's right face after the treatment;
图2为治疗结束后受试者左脸的皮肤状况。Figure 2 shows the skin condition of the subject's left face after the end of the treatment.
具体实施方式Detailed ways
下面将结合实施例对本发明的实施方案进行详细描述,但是本领域技术人员将会理解,下列实施例仅用于说明本发明,而不应视为限制本发明的范围。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市购买获得的常规产品。The embodiments of the present invention will be described in detail below with reference to the examples, but those skilled in the art will understand that the following examples are only used to illustrate the present invention and should not be regarded as limiting the scope of the present invention. If the specific conditions are not indicated in the examples, it is carried out according to the conventional conditions or the conditions suggested by the manufacturer. The reagents or instruments used without the manufacturer's indication are conventional products that can be purchased in the market.
实施例1Example 1
一种用于治疗痤疮的敷料,包括敷料液和敷料基底,其中,按重量份计,所述敷料液主要由1份海洋水解胶原蛋白、0.5份甘草酸二钾、0.2份芦荟凝胶粉和1000份水制备而成;所述敷料基底为壳聚糖无纺布,其中,壳聚糖的质量分数为20%。A dressing for treating acne, comprising a dressing liquid and a dressing base, wherein, in parts by weight, the dressing liquid is mainly composed of 1 part of marine hydrolyzed collagen, 0.5 part of dipotassium glycyrrhizinate, 0.2 part of aloe vera gel powder and 1000 parts of water; the dressing base is chitosan non-woven fabric, wherein the mass fraction of chitosan is 20%.
所述海洋水解胶原蛋白为Nippi水解胶原蛋白,所述芦荟凝胶粉为库拉索芦荟凝胶粉。The marine hydrolyzed collagen is Nippi hydrolyzed collagen, and the aloe vera gel powder is aloe vera gel powder.
辅料具体制备方法包括:1、在无菌环境下,将海洋水解胶原蛋白、甘草酸二钾和芦荟凝胶粉加入到纯化水中,搅拌溶解即得辅料液。2、在无菌环境下,将前述辅料液与壳聚糖无纺布混合,封装,之后辐照灭菌。The specific preparation method of the auxiliary material includes: 1. In a sterile environment, the marine hydrolyzed collagen, dipotassium glycyrrhizate and aloe vera gel powder are added into purified water, and the auxiliary material solution is obtained by stirring and dissolving. 2. In a sterile environment, mix the aforementioned adjuvant liquid with chitosan non-woven fabric, package, and then sterilize by irradiation.
实施例2Example 2
参照实施例1所述方法制备敷料,区别仅在于:所述敷料液主要由5 份海洋水解胶原蛋白、2份甘草酸二钾、1份芦荟凝胶粉和1000份水制备而成;所述无纺布中壳聚糖的质量分数为30%。The dressing was prepared with reference to the method described in Example 1, except that the dressing solution was mainly prepared from 5 parts of marine hydrolyzed collagen, 2 parts of dipotassium glycyrrhizinate, 1 part of aloe vera gel powder and 1000 parts of water; The mass fraction of chitosan in the non-woven fabric is 30%.
实施例3Example 3
参照实施例1所述方法制备敷料,区别仅在于:所述敷料液主要由10 份海洋水解胶原蛋白、4份甘草酸二钾、1份芦荟凝胶粉和1000份水制备而成;所述无纺布中壳聚糖的质量分数为100%。The dressing was prepared with reference to the method described in Example 1, except that the dressing solution was mainly prepared from 10 parts of marine hydrolyzed collagen, 4 parts of dipotassium glycyrrhizinate, 1 part of aloe vera gel powder and 1000 parts of water; The mass fraction of chitosan in the non-woven fabric is 100%.
实施例4Example 4
参照实施例2所述方法制备敷料,区别仅在于:所述无纺布中壳聚糖的质量分数为50%。The dressing was prepared with reference to the method described in Example 2, except that the mass fraction of chitosan in the non-woven fabric was 50%.
实施例5Example 5
参照实施例2所述方法制备敷料,区别仅在于:所述无纺布中壳聚糖的质量分数为100%。The dressing was prepared according to the method described in Example 2, except that the mass fraction of chitosan in the non-woven fabric was 100%.
实施例6Example 6
参照实施例1所述方法制备敷料,区别仅在于,所述海洋水解胶原蛋白为罗赛洛海洋水解胶原蛋白。The dressing was prepared with reference to the method described in Example 1, except that the marine hydrolyzed collagen was Rousselot marine hydrolyzed collagen.
实施例7Example 7
参照实施例1所述方法制备敷料,区别仅在于,所述海洋水解胶原蛋白为东方海洋水解胶原蛋白。The dressing was prepared with reference to the method described in Example 1, except that the marine hydrolyzed collagen was oriental marine hydrolyzed collagen.
实施例8Example 8
参照实施例1所述方法制备敷料,区别仅在于,所述海洋水解胶原蛋白为山东长久海洋水解胶原蛋白。The dressing was prepared with reference to the method described in Example 1, the only difference being that the marine hydrolyzed collagen was Shandong Changchang marine hydrolyzed collagen.
实施例9Example 9
参照实施例1所述方法制备敷料,区别仅在于,在制备过程中,所述敷料液与所述敷料基底独立包装和灭菌处理。The dressing was prepared with reference to the method described in Example 1, the only difference being that, during the preparation process, the dressing liquid and the dressing base were packaged and sterilized independently.
实验例1Experimental example 1
检测前述实施例所用海洋水解胶原蛋白的理化性质及其酪氨酸酶抑制率,其中,具体的检测方式和检测结果如下所示。The physicochemical properties and tyrosinase inhibition rate of the marine hydrolyzed collagen used in the foregoing examples were detected, wherein the specific detection methods and detection results are shown below.
1、采用高效体积排阻色谱法,检测不同品牌的海洋水解胶原蛋白 (Nippi、罗赛洛、东方海洋和山东天久)的分子量大小和聚合物分散性指数(PDI),具体检测结果如表1所示。1. High-efficiency size exclusion chromatography was used to detect the molecular weight and polymer dispersibility index (PDI) of different brands of marine hydrolyzed collagen (Nippi, Rousselot, Oriental Ocean and Shandong Tianjiu). The specific test results are shown in Table 1. shown.
表1不同海洋水解胶原蛋白的理化性质Table 1 Physicochemical properties of different marine hydrolyzed collagens
2、采用蘑菇酪氨酸酶多巴速率氧化法检测不同品牌海洋水解胶原蛋白的酪氨酸酶抑制率,具体检测方法和检测结果如下所示。2. The tyrosinase inhibition rate of different brands of marine hydrolyzed collagen was detected by the mushroom tyrosinase dopa rate oxidation method. The specific detection methods and results are shown below.
1)样品处理:用超纯水将不同品牌的海洋水解胶原蛋白配成10g/L的溶液(酪氨酸酶是铜蛋白,溶液中不应含有铜离子)作为样品液备用。1) Sample processing: Use ultrapure water to prepare a 10g/L solution of different brands of marine hydrolyzed collagen (tyrosinase is copper protein, and the solution should not contain copper ions) as a sample solution for later use.
2)实验操作:在玻璃管中进行生化反应,各管加入所需要的pH6.8磷酸缓冲液(磷酸氢二钾6.8g和氢氧化钠0.944g定容至1000ml)、样品液、曲酸溶液(10g/L)和酶溶液(约3.5mg酪氨酸酶定容至100ml)于37℃水浴中反应10min,再依次加入L-多巴溶液(2.5g/L),于37℃水浴中反应 10min,测475nm波长的吸光值。实验体系设计见表2。2) Experimental operation: carry out the biochemical reaction in a glass tube, add the required pH6.8 phosphate buffer (6.8g dipotassium hydrogen phosphate and 0.944g sodium hydroxide to 1000ml), sample solution, and kojic acid solution to each tube. (10g/L) and enzyme solution (about 3.5mg tyrosinase to 100ml) were reacted in a water bath at 37°C for 10min, and then L-dopa solution (2.5g/L) was added in turn, and the reaction was performed in a water bath at 37°C 10min, measure the absorbance at 475nm wavelength. The experimental system design is shown in Table 2.
表2实验体系设计表Table 2 Experimental system design table
3)抑制率计算方法:样品对酪氨酸酶活性的抑制强度以抑制率表示。样品抑制率=[阳性对照吸光度值-(样品管吸光度值-阴性对照吸光度值)]/ 阳性对照吸光度值×100%,标准对照抑制率=(阳性对照吸光值-标准管吸光值)/阳性对照吸光值×100%,抑制率高表明其对酶活性抑制强度最高。标准品参比:为保证实验结果的准确性,在实验室做检测都应设有标准品对照。选用曲酸作为标准对照,不同批次实验时,曲酸标准对照的抑制率会有所不同,可以将标准对照的抑制率折算成100%,受试物的抑制率等比例变化后再作比较。如按照上述公式计算出受试物的抑制率为18%,标准对照物抑制率为90%,折算后的受试物抑制率为18%/90%=20%。3) Calculation method of inhibition rate: The inhibition strength of samples to tyrosinase activity is expressed as inhibition rate. Sample inhibition rate=[positive control absorbance value-(sample tube absorbance value-negative control absorbance value)]/positive control absorbance value×100%, standard control inhibition rate=(positive control absorbance value-standard tube absorbance value)/positive control Absorbance value × 100%, high inhibition rate indicates that it has the highest inhibitory intensity on enzyme activity. Standard reference: In order to ensure the accuracy of the experimental results, there should be a standard reference for testing in the laboratory. Kojic acid is selected as the standard control. In different batches of experiments, the inhibition rate of the kojic acid standard control will be different. The inhibition rate of the standard control can be converted into 100%, and the inhibition rate of the test substance is changed in equal proportions before making a comparison. . For example, according to the above formula, the inhibition rate of the test substance is 18%, the inhibition rate of the standard control substance is 90%, and the converted inhibition rate of the test substance is 18%/90%=20%.
表3不同品牌海洋水解胶原蛋白的酪氨酸酶抑制率Table 3 Tyrosinase inhibition rate of different brands of marine hydrolyzed collagen
2、检测结果分析:根据表1所示海洋水解胶原蛋白的分子量与聚合物分散性指数以及表3所示酪氨酸酶抑制率可知,海洋水解胶原蛋白的酪氨酸酶抑制率与其分子量、PDI等有关,其中,分子量在1000道尔顿以下、 PDI指数在2.4以下的海洋水解胶原蛋白对酪氨酸酶具有良好的抑制效果。2. Analysis of test results: According to the molecular weight and polymer dispersibility index of marine hydrolyzed collagen shown in Table 1 and the tyrosinase inhibition rate shown in Table 3, the tyrosinase inhibition rate of marine hydrolyzed collagen is related to its molecular weight, Among them, marine hydrolyzed collagen with molecular weight below 1000 Daltons and PDI index below 2.4 has a good inhibitory effect on tyrosinase.
实验例2Experimental example 2
取实施例5所用原料以及敷料成品,检测其细胞毒性,其具体检测方法参照国标GB/T 16886.5-2003/ISO 10993-5:1999,具体检测结果如表4所示。Take the raw materials used in Example 5 and the finished dressing, and detect its cytotoxicity. The specific detection method refers to the national standard GB/T 16886.5-2003/ISO 10993-5:1999, and the specific detection results are shown in Table 4.
根据检测所得细胞相对增殖率(relative growth rate,RGR)对样品进行毒性分级和合格性判定,其具体分级标准为:According to the relative growth rate (RGR) of the detected cells, the samples are classified for toxicity and eligibility. The specific grading standards are as follows:
0级:RCG≥100%;1级:99%≥RCG≥75;2级:74≥RCG≥50;3 级:49≥RCG≥25;4级:24≥RGR≥1;5级=0。Grade 0: RCG≥100%; Grade 1: 99%≥RCG≥75; Grade 2: 74≥RCG≥50; Grade 3: 49≥RCG≥25; Grade 4: 24≥RGR≥1; Grade 5=0.
样品合格判定标准:0~1级别为合格;根据细胞形态综合分析判定2 级是否为合格、3~5级为不合格。Qualification criteria for samples: 0 to 1 grades are qualified; according to comprehensive analysis of cell morphology, 2 grades are qualified, and 3 to 5 grades are unqualified.
根据表4所述实验结果可知,本发明涉及的原料以及成品均无细胞毒性,安全可靠。According to the experimental results described in Table 4, the raw materials and finished products involved in the present invention have no cytotoxicity and are safe and reliable.
表4细胞毒性试验结果Table 4 Cytotoxicity test results
实验例3Experimental example 3
取实施例1~5所述敷料,检测其对金黄色葡萄球菌(ATCC6538)和痤疮丙酸杆菌(ATCC11827)的抑制作用,具体检测方法参见国标GB/T 20944,具体检测结果参见表5。根据表5所示试验结果可知,本发明所述敷料对金黄色葡萄球菌和痤疮丙酸杆菌具有良好的抑菌作用。The dressings described in Examples 1 to 5 were taken, and their inhibitory effects on Staphylococcus aureus (ATCC6538) and Propionibacterium acnes (ATCC11827) were tested. For specific detection methods, refer to the national standard GB/T 20944, and specific test results refer to Table 5. According to the test results shown in Table 5, the dressing of the present invention has a good bacteriostatic effect on Staphylococcus aureus and Propionibacterium acnes.
表5抑菌试验结果Table 5 Bacteriostatic test results
实验例4Experimental example 4
召集两名受试者,对实施例5所述敷料进行试用,具体情况如下所示:Two subjects were called to try the dressing described in Example 5, and the details were as follows:
1、受试者1. Subject
数量:2名;性别:男;年龄:25~33岁;生理状况:面部中度痤疮,常年红肿,痤疮较硬。Number: 2; Gender: Male; Age: 25-33 years old; Physiological condition: moderate acne on the face, perennial redness and swelling, and hard acne.
2、试验方法2. Test method
半脸实验,2人均为右半边脸使用本发明实施例4所述敷料,左半边脸作为对照。实验周期4周,前10天每天使用敷料1次,使用时间为20~30min/ 次,以后每周使用2~3次,使用时间为20~30min/次。In the half-face experiment, 2 people used the dressing described in Example 4 of the present invention on the right half of the face, and the left half of the face was used as a control. The experimental period was 4 weeks. The dressing was used once a day for the first 10 days for 20-30 min/time, and then 2-3 times a week for 20-30 min/time.
3、试验结果3. Test results
试验结束后,召集7~8人对两名受试者的左右脸皮肤状况进行盲评,均认为二人右侧皮肤的面部痤疮明显减少、疤痕减淡、光泽度增加,皮肤整体状况显著优于左侧皮肤。其中一名受试者在试验结束后的左右脸部皮肤的对照结果如图1~2所示,根据图中所示结果可知,经过敷料治疗后,受试者的右脸痤疮状况得到明显改善。After the test, 7-8 people were called to blindly evaluate the skin condition of the left and right faces of the two subjects. They all believed that the facial acne on the right side of the two subjects was significantly reduced, the scars were reduced, and the gloss was increased, and the overall skin condition was significantly better. on the left skin. The control results of the left and right facial skin of one of the subjects after the test are shown in Figures 1 to 2. According to the results shown in the figure, after the dressing treatment, the subject's acne condition on the right face was significantly improved .
最后应说明的是:以上各实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述各实施例对本发明进行了详细的说明,但本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分或者全部技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的范围。Finally, it should be noted that: the above embodiments are only used to illustrate the technical solutions of the present invention, but not to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, those of ordinary skill in the art should understand: It is still possible to modify the technical solutions recorded in the foregoing embodiments, or perform equivalent replacements for some or all of the technical features; and these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the technical solutions of the embodiments of the present invention. range.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810119795.6A CN108210975B (en) | 2018-02-06 | 2018-02-06 | Collagen Dressing for Acne Treatment |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810119795.6A CN108210975B (en) | 2018-02-06 | 2018-02-06 | Collagen Dressing for Acne Treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108210975A CN108210975A (en) | 2018-06-29 |
CN108210975B true CN108210975B (en) | 2020-12-22 |
Family
ID=62670721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810119795.6A Active CN108210975B (en) | 2018-02-06 | 2018-02-06 | Collagen Dressing for Acne Treatment |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108210975B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109106665A (en) * | 2018-08-31 | 2019-01-01 | 青岛银色世纪健康产业集团有限公司 | A kind of Marine biologic peptide anti-acne repairs facial mask and preparation method thereof |
CN109381365A (en) * | 2018-12-29 | 2019-02-26 | 上海家化联合股份有限公司 | Thickener blend composition containing dipotassium glycyrrhizinate |
CN111743788A (en) * | 2020-06-29 | 2020-10-09 | 华仁药业股份有限公司 | Collagen dressing containing icodextrin |
CN113577364A (en) * | 2021-08-13 | 2021-11-02 | 常州谙美生物科技有限公司 | Medical dressing for after-sun repair |
CN113616850A (en) * | 2021-09-02 | 2021-11-09 | 长春工业大学 | A kind of highly transparent skin repairing hydrogel dressing and preparation method thereof |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6248763B1 (en) * | 1998-05-19 | 2001-06-19 | Scivoletto Rosemarie | Composition for treating skin conditions |
CN1813668A (en) * | 2005-12-07 | 2006-08-09 | 陕西博森生物制药股份集团有限公司 | Whitening wrinkle-removing face paster and method for preparing its product |
KR20100006051A (en) * | 2008-07-08 | 2010-01-18 | 윤영빈 | Massage mud pack containing ligneous clay |
CN105126151A (en) * | 2015-09-30 | 2015-12-09 | 陕西艾尔肤组织工程有限公司 | Collagen dressing plaster and preparing method and application thereof |
CN105326684A (en) * | 2015-10-30 | 2016-02-17 | 苏州靓因子生物技术有限公司 | Skin repairing liquid and application thereof |
CN105536027A (en) * | 2015-12-24 | 2016-05-04 | 南阳市汇博生物技术有限公司 | Scar treatment strip capable of lowering tissue tension and preparation method thereof |
CN106265318A (en) * | 2016-08-31 | 2017-01-04 | 祖亚宾 | Prevention and the cosmetics dispelling skin sore acne and preparation method thereof |
CN106692012A (en) * | 2016-11-17 | 2017-05-24 | 广西久益盈家信息技术有限公司 | Cell repair lotion for supplying nutrients |
CN106726764A (en) * | 2016-12-25 | 2017-05-31 | 江西宜信堂医疗科技有限公司 | A kind of anti-acne essence and preparation method thereof |
CN107049880A (en) * | 2017-06-16 | 2017-08-18 | 湖南御家化妆品制造有限公司 | Lightening compositions and its application |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999064081A1 (en) * | 1998-06-08 | 1999-12-16 | Ferris Corporation | Analgesic and antinociceptive methods |
WO2009046116A1 (en) * | 2007-10-01 | 2009-04-09 | Dennis Gross | Skin care products containing multiple enhancers |
CN105816498A (en) * | 2009-04-27 | 2016-08-03 | 玫琳凯有限公司 | Botanical anti-acne formulations |
KR20220029786A (en) * | 2011-04-06 | 2022-03-08 | 마리 케이 인코포레이티드 | Topical skin care formulations comprising plant extracts |
US20150174254A1 (en) * | 2013-12-23 | 2015-06-25 | Mcneil-Ppc, Inc. | Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent |
CN105797279B (en) * | 2016-03-03 | 2018-06-22 | 广东顺德安信药业有限公司 | Multifunctional far infrared negative ions magnet therapy silica gel beauty care device and mating cosmetics |
CN105688262A (en) * | 2016-03-14 | 2016-06-22 | 苏州市贝克生物科技有限公司 | Preparation method of scar-removing biological dressing |
-
2018
- 2018-02-06 CN CN201810119795.6A patent/CN108210975B/en active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6248763B1 (en) * | 1998-05-19 | 2001-06-19 | Scivoletto Rosemarie | Composition for treating skin conditions |
CN1813668A (en) * | 2005-12-07 | 2006-08-09 | 陕西博森生物制药股份集团有限公司 | Whitening wrinkle-removing face paster and method for preparing its product |
KR20100006051A (en) * | 2008-07-08 | 2010-01-18 | 윤영빈 | Massage mud pack containing ligneous clay |
CN105126151A (en) * | 2015-09-30 | 2015-12-09 | 陕西艾尔肤组织工程有限公司 | Collagen dressing plaster and preparing method and application thereof |
CN105326684A (en) * | 2015-10-30 | 2016-02-17 | 苏州靓因子生物技术有限公司 | Skin repairing liquid and application thereof |
CN105536027A (en) * | 2015-12-24 | 2016-05-04 | 南阳市汇博生物技术有限公司 | Scar treatment strip capable of lowering tissue tension and preparation method thereof |
CN106265318A (en) * | 2016-08-31 | 2017-01-04 | 祖亚宾 | Prevention and the cosmetics dispelling skin sore acne and preparation method thereof |
CN106692012A (en) * | 2016-11-17 | 2017-05-24 | 广西久益盈家信息技术有限公司 | Cell repair lotion for supplying nutrients |
CN106726764A (en) * | 2016-12-25 | 2017-05-31 | 江西宜信堂医疗科技有限公司 | A kind of anti-acne essence and preparation method thereof |
CN107049880A (en) * | 2017-06-16 | 2017-08-18 | 湖南御家化妆品制造有限公司 | Lightening compositions and its application |
Also Published As
Publication number | Publication date |
---|---|
CN108210975A (en) | 2018-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108210975B (en) | Collagen Dressing for Acne Treatment | |
Zeng et al. | Tailoring food biopolymers into biogels for regenerative wound healing and versatile skin bioelectronics | |
Yang et al. | Integrated photo-inspired antibacterial polyvinyl alcohol/carboxymethyl cellulose hydrogel dressings for pH real-time monitoring and accelerated wound healing | |
CN114984301B (en) | Antibacterial dressing for promoting wound surface to heal without scars and preparation method thereof | |
CN109106665A (en) | A kind of Marine biologic peptide anti-acne repairs facial mask and preparation method thereof | |
CN113876801A (en) | Protein selenium nano enzyme and preparation method and application thereof | |
CN107375032A (en) | A kind of composition and preparation method for repairing skin barrier | |
CN108743921A (en) | It is a kind of to prevent the reparation liquid and its preparation method and application that scar is formed | |
CN107714631B (en) | Collagen peptide mask liquid and preparation method thereof | |
CN105749333B (en) | A kind of hyaluronic acid medical dressing and preparation method thereof | |
CN108815584A (en) | One kind is for curing medical epoxy resin of U.S. complex function and preparation method thereof | |
CN105031674A (en) | Disinfectant medical ultrasonic coupling agent and production process thereof | |
US12268711B2 (en) | Methods for preparing products for treating scald infection caused by Pseudomonas aeruginosa | |
CN105581964A (en) | Product for rejuvenating and beautifying and preparation method thereof | |
CN118718080A (en) | Preparation and application of Ti3C2Tx MXene-based conductive antibacterial hydrogel dressing | |
CN112472647A (en) | Medical cold dressing for skin repair and preparation method thereof | |
CN118121538A (en) | Ointment for wound surface nursing and preparation method thereof | |
CN110141678A (en) | A kind of alginates physical therapy liquid dressing and preparation method thereof | |
CN117482003A (en) | Special absorbable gel for beauty instrument and preparation method thereof | |
CN103007334B (en) | A liquid wound repair film and its preparation method | |
CN104306922A (en) | Inflammation-diminishing pain-relieving hydrogel and preparation method thereof | |
CN100502953C (en) | active wound repair material | |
CN114957511A (en) | Algin oligosaccharide zinc and preparation method and application thereof | |
CN111000871A (en) | Oral cavity spray and preparation method thereof | |
JPH09227387A (en) | Drug externally using for treatment of atopic dermatitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220623 Address after: 266000 No. 23 Hong Kong East Road, Laoshan District, Qingdao City, Shandong Province Patentee after: Haisheng Health Technology (Qingdao) Co.,Ltd. Patentee after: Qingdao Institute of marine biomedicine Address before: 266000 No. 23 Hong Kong East Road, Laoshan District, Qingdao City, Shandong Province Patentee before: MARINE BIOMEDICAL Research Institute OF QINGDAO |